Phase II Trial to Evaluate the Efficacy of Topical Bexarotene Gel in Patients With Parapsoriasis

Stopped early · Phase 2

Conditions studied: Parapsoriasis

In brief

Parapsoriasis is a term that refers to a precursor stage of cutaneous T-cell lymphoma (CTCL)/mycosis fungoides(MF). Complete responses (clearing) of early presentations of CTCL/MF have been shown to be associated with long-term survival and cure. Induction of a complete response in parapsoriasis, therefore, would seem to be a desirable therapeutic endpoint. Bexarotene 1% gel has been approved for treatment of cutaneous T-cell lymphoma (mycosis fungoides). The goal of this study is to evaluate the tolerability, safety and efficacy of bexarotene 1% gel in patients with parapsoriasis.

Key facts

Study ID

NCT00322296

Run by

Fox Chase Cancer Center

People needed

8

Starts

2001-04-01

Expected to finish

2004-08-01

Last updated by the study team

2013-04-16

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• A clinical and histologic diagnosis of parapsoriasis (T0 CTCL)
• Age 18 years or older.
• Acceptable laboratory studies
• Must be free of serious concurrent illness.
• Women of child-bearing potential must have negative serum pregnancy test prior to the initiation of treatment.

You may not qualify if…

• Topical or systemic therapies within four weeks of entry in the study.
• Participation in any other investigational drug study within thirty days of entry in this study.
• Oral retinoid therapy for any indication within three months of entry in the study.
• Participation in any other study using topical retinoid therapy.
• Pregnancy or active breast-feeding.
• Serious known concurrent medical illness or infection.

Where it is running

• Fox Chase Cancer Center — Philadelphia, Pennsylvania, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.